Shanghai Pharma Stock Continues Fall Despite Denial Of Securities Investigation
This article was originally published in PharmAsia News
Executive Summary
Refuting an investigation and M&A malfeasance hasn't prevented shares from tumbling for Shanghai Pharma, which has Pfizer Inc. as a cornerstone investor.
You may also be interested in...
With Pfizer As Cornerstone Investor, Will Shanghai Pharmaceutical Be Largest Pharma IPO Ever?
SHANGHAI - Shanghai Pharmaceutical Holdings Co. Ltd is set for what could be the largest IPO by a pharmaceutical company ever, surpassing Ostuka Holding's $2.4 billion IPO from last year
Southeast Asian Regulators Ramp Up Anti-Corruption, Bribery Enforcement Ahead of ASEAN Pact
Regulators in Southeast Asia are working to tighten bribery and corruption enforcement as part of a broader push ahead of an Association of Southeast Asian Nations trade pact in 2015 for greater transparency in pharmaceuticals.
St. Jude Introduces Allure Quadra To Hong Kong As It Seeks APAC Rebound For Pacemakers
The first commercial implant for St. Jude’s Allure Quadra in Hong Kong is a sign for optimism for its pacemaker business after last year’s disappointments in Japan.